Neil Came

517 total citations
17 papers, 308 citations indexed

About

Neil Came is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Neil Came has authored 17 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 10 papers in Genetics and 7 papers in Oncology. Recurrent topics in Neil Came's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Neil Came is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Neil Came collaborates with scholars based in Australia, United Kingdom and United States. Neil Came's co-authors include David Westerman, John F. Seymour, Ruth de Tute, Jo‐Anne Vergilio, Bruno Paiva, Anand S. Lagoo, Pei Lin, Weina Chen, Maria Arroz and Constance M. Yuan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Neil Came

17 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil Came Australia	8	186	148	106	106	74	17	308
Sujaatha Narayanan Canada	10	181 1.0×	81 0.5×	67 0.6×	63 0.6×	61 0.8×	43	272
Qi Gao United States	9	180 1.0×	67 0.5×	118 1.1×	100 0.9×	126 1.7×	30	308
Renee Ward United States	8	196 1.1×	164 1.1×	125 1.2×	84 0.8×	53 0.7×	11	320
Efstathios Koulieris Greece	10	141 0.8×	106 0.7×	88 0.8×	85 0.8×	103 1.4×	24	262
Rebeca Cuello Spain	8	115 0.6×	171 1.2×	104 1.0×	123 1.2×	48 0.6×	10	289
Ashley F. Ward United States	5	139 0.7×	112 0.8×	146 1.4×	65 0.6×	72 1.0×	6	290
Stefan Koehrer United States	9	64 0.3×	110 0.7×	125 1.2×	69 0.7×	83 1.1×	14	287
Dennis Veldhuizen Netherlands	6	180 1.0×	57 0.4×	81 0.8×	106 1.0×	87 1.2×	7	316
Laurie Musial United States	5	135 0.7×	265 1.8×	104 1.0×	219 2.1×	71 1.0×	8	350
Rose Mantel United States	8	98 0.5×	254 1.7×	112 1.1×	193 1.8×	59 0.8×	13	327

Countries citing papers authored by Neil Came

Since Specialization

Citations

This map shows the geographic impact of Neil Came's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Came with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Came more than expected).

Fields of papers citing papers by Neil Came

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Came. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Came. The network helps show where Neil Came may publish in the future.

Co-authorship network of co-authors of Neil Came

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Came. A scholar is included among the top collaborators of Neil Came based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Came. Neil Came is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Nguyen, Phillip, Tamia Nguyen, Ing Soo Tiong, et al.. (2023). Evaluation of T‐cell clonality by anti‐TRBC1 antibody‐based flow cytometry and correlation with T‐cell receptor sequencing. British Journal of Haematology. 204(3). 910–920. 2 indexed citations

Nguyen, Phillip, et al.. (2023). Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia. British Journal of Haematology. 202(4). 760–770. 4 indexed citations

Nguyen, Phillip, Vuong Nguyen, Neil Came, & David Westerman. (2022). Unsupervised computational detection of measurable residual disease in chronic lymphocytic leukaemia. Pathology. 54. S30–S31. 1 indexed citations

Maclachlan, Kylee, Neil Came, Benjamin Diamond, et al.. (2021). Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. Pathology. 53(3). 385–399. 16 indexed citations

Lew, Thomas E., Mary Ann Anderson, Victor S. Lin, et al.. (2020). Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Advances. 4(1). 165–173. 31 indexed citations

Nguyen, Vuong, et al.. (2020). Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma. Cytometry Part B Clinical Cytometry. 98(5). 385–398. 9 indexed citations

Arroz, Maria, Neil Came, Pei Lin, et al.. (2015). Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry Part B Clinical Cytometry. 90(1). 31–39. 113 indexed citations

Yannakou, Costas K., Neil Came, Ashish Bajel, & Surender Juneja. (2015). CD19 Negative Relapse in B-ALL Treated with Blinatumomab Therapy: Avoiding the Trap. Blood. 126(23). 4983–4983. 6 indexed citations

Herbert, Kirsten, Glen Wiesner, Emma Link, et al.. (2014). Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Bone Marrow Transplantation. 49(8). 1056–1062. 12 indexed citations

10.

Grigoriadis, George, et al.. (2012). Is CD20 positive plasma cell myeloma a unique clinicopathological entity? A study of 40 cases and review of the literature. Pathology. 44(6). 552–556. 14 indexed citations

11.

Pasricha, Sant‐Rayn, Surender Juneja, David Westerman, & Neil Came. (2011). Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenström macroglobulinaemia. Journal of Clinical Pathology. 64(6). 520–523. 16 indexed citations

12.

Carney, Dennis, David Westerman, Constantine S. Tam, et al.. (2010). Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 24(12). 2056–2062. 68 indexed citations

13.

Lee, Rebecca, Nicole Ritz, Stuart P. Berzins, et al.. (2010). Lessons Learned From an Unusual Presentation of CD3⁺, CD56⁻ T-Cell Large Granular Lymphocyte Leukemia. Journal of Clinical Oncology. 28(28). e498–e502. 1 indexed citations

14.

Herbert, Kirsten, Glen Wiesner, Emma Link, et al.. (2010). Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients. Blood. 116(21). 2256–2256. 3 indexed citations

15.

Burbury, Kate, Peter Gambell, Neil Came, et al.. (2009). Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.. Blood. 114(22). 2767–2767. 1 indexed citations

16.

Evans, D. Gareth, et al.. (2002). MonoFIX‐VF, a new mono‐component factor IX concentrate: a single‐centre continuous‐infusion study. Haemophilia. 8(5). 635–638. 4 indexed citations

17.

Came, Neil, et al.. (2002). Autologous peripheral blood stem cell transplantation for peripheral neuropathy secondary to monoclonal gammopathy of unknown significance. Bone Marrow Transplantation. 30(1). 53–56. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact